Related Experiment Video
Updated: Jun 12, 2025

Noninvasive Intratracheal Lipopolysaccharide Instillation in Mice
Published on: March 31, 2023
JAK-inhibitor Tofacitinib in Severe Laryngeal Sarcoidosis: A Case Report
Meryem Demir1,2, Vasileios Kouranos1, Kostadin Stoenchev1
1Royal Brompton Hospital London, Guy's, and St Thomas' NHS Foundation Trust, London, UK.
Abstract:
Sarcoidosis is an inflammatory, non-caseating granulomatous multisystem disease associated with JAK-STAT (Janus kinases-signal transducer and activator of transcription proteins) pathway activation. We present a patient with severe multi-systemic sarcoidosis who showed marked improvement with tofacitinib with regards to pulmonary, cutaneous, nasal and laryngeal disease. Tofacitinib prevented critical laryngeal stenosis from progressing to tracheostomy, induced regression of cutaneous lesions and improved pulmonary function in this steroid-resistant and immunosuppressive intolerant case. This case report supports further the role of JAK-inhibitors in the treatment of systemic sarcoidosis. Laryngoscope, 135:829-832, 2025.

